Neos Therapeutics Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Neos Therapeutics, Inc.
– Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic – – Company to host...
RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer
May 06, 2020 09:25 ET
|
RespireRX Pharmaceuticals Inc.
Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer Glen Rock, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc....
Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020
May 04, 2020 16:05 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin
April 09, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, April 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Statement: COVID-19 Update
March 30, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Jerry McLaughlin, President and CEO, made the following statement: We want to share the steps we are taking to ensure healthcare...
Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
March 13, 2020 07:47 ET
|
Neos Therapeutics, Inc.
– Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1...
Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020
March 06, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
February 26, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
February 12, 2020 09:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”)...
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
February 05, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...